廣告
香港股市 已收市
  • 恒指

    16,541.42
    +148.58 (+0.91%)
     
  • 國指

    5,810.79
    +82.66 (+1.44%)
     
  • 上證綜指

    3,025.56
    +14.90 (+0.49%)
     
  • 滬深300

    3,523.43
    +2.47 (+0.07%)
     
  • 美元

    7.8258
    +0.0002 (+0.00%)
     
  • 人民幣

    0.9229
    +0.0001 (+0.01%)
     
  • 道指

    39,807.37
    +47.29 (+0.12%)
     
  • 標普 500

    5,254.35
    +5.86 (+0.11%)
     
  • 納指

    16,379.46
    -20.06 (-0.12%)
     
  • 日圓

    0.0515
    +0.0000 (+0.06%)
     
  • 歐元

    8.4331
    -0.0075 (-0.09%)
     
  • 英鎊

    9.8760
    0.0000 (0.00%)
     
  • 紐約期油

    83.11
    -0.06 (-0.07%)
     
  • 金價

    2,254.80
    +16.40 (+0.73%)
     
  • Bitcoin

    70,360.77
    +704.90 (+1.01%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

Gossamer Bio Shares Plummet As Hypertension Trial Fall Short Of Expectation

  • Gossamer Bio Inc (NASDAQ: GOSS) announced topline results for the TORREY Phase 2 study of seralutinib in patients with pulmonary arterial hypertension (PAH).

  • A mean difference in pulmonary vascular resistance (PVR) between the placebo and seralutinib arms of -96.1 dynes, equating to a placebo-corrected improvement of 14.3%, was observed in the study.

  • An observed mean difference in six-minute walk distance (6MWD) between placebo and seralutinib of 6.5 meters numerically favored the seralutinib arm.

  • Enhanced effects for both PVR and 6MWD were observed in patients with more severe baseline disease.

  • Related: Analyst Expects 'Somewhat Smaller Effect Size' From Gossamer Bio's Upcoming PAH Trial.

  • In FC III patients, a 21% reduction in PVR and 37m improvement in 6MWD were observed for the seralutinib arm vs. placebo.

  • Seralutinib treatment resulted in a statistically significant reduction in NT-proBNP, a biomarker of right heart stress, as early as 12 weeks, increasing to a 408.3 ng/L mean difference from placebo at Week 24.

  • Seralutinib was generally well tolerated in the TORREY study, with treatment-emergent adverse events (TEAEs) reported in 36 (86%) and 41 (93%) of the patients in the placebo and seralutinib arms, respectively.

  • Price Action: GOSS shares are down 67.70% at $3.00 on the last check Tuesday.

See more from Benzinga

廣告

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.